HLA-C and hematologic disorder: Due to their features including non-MHC restriction, cytotoxicity against hematological malignancies and capacity for ADCC, γδ T cells are promising effector cells for immunotherapy of pediatric B-lineage ALL during early post-transplant phase and phase and cell-based immunotherapy after SCT.